Novel M2 -selective, Gi -biased agonists of muscarinic acetylcholine receptors.

The identified compounds may serve as lead structures in the search for novel non-steroidal and non-opioid analgesics acting via M2 and M4 muscarinic receptors with reduced side effects associated with activation of the phospholipase C signalling pathway.